Meanwhile, it improves cardiac function in diabetic rats by reducing collagen deposition and GSDMD-mediated pyroptosis via upregulating miR-135b [110], implying that ranolazine may have clinical value as a treatment for DCM. This evidence concerns the gene GSDMD and familial dilated cardiomyopathy.